Journal article

Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics

Lisa J Phillips, Barnaby Nelson, Hok Pan Yuen, Shona M Francey, Magenta Simmons, Carrie Stanford, Margaret Ross, Daniel Kelly, Kathryn Baker, Philippe Conus, Paul Amminger, Francois Trumpler, Yang Yun, Michelle Lim, Catharine McNab, Alison R Yung, Patrick D McGorry



OBJECTIVE: Intervention during the pre-psychotic period of illness holds the potential of delaying or even preventing the onset of a full-threshold disorder, or at least of reducing the impact of such a disorder if it does develop. The first step in realizing this aim was achieved more than 10 years ago with the development and validation of criteria for the identification of young people at ultra-high risk (UHR) of psychosis. Results of three clinical trials have been published that provide mixed support for the effectiveness of psychological and pharmacological interventions in preventing the onset of psychotic disorder. METHOD: The present paper describes a fourth study that has now been ..

View full abstract


Awarded by Janssen Cilag

Funding Acknowledgements

We gratefully acknowledge the young people and their families who agreed to involvement in this trial as well as the numerous clinicians and research staff who assisted in conducting this research. We gratefully acknowledge the financial and additional support of Janssen Cilag in the conduct ofthis study. In particular we thank Dr Ivo Caers for his personal advocacy for this project and Claire Methven for her constant and good-humoured support over several years. Funding was provided through a major investigator-initiated grant from Janssen-Cilag Pharmaceuticals (RIS-AUS-9). Janssen- Cilag had no further role in study design, in the collection, analysis and interpretation of data, in the writing ofthis report and in the decision to submit this paper for publication. Janssen- Cilag did provide assistance with monitoring the trial and assuring quality of data collection and recording over the treatment phase. Alison Yung, Lisa Phillips and Patrick McGorry have received investigator- initiated funding from Janssen Pharmaceuticals; Patrick McGorry has received investigator- initiated funding from Astra-Zeneca.